Covid-19 manufacturing roundup: Ritonavir production to reach 100M doses annually; Schumer calls for a boost to domestic vaccine supply

Josh Sullivan

Amid the spike in positive Covid-19 cases thanks to the Omicron variant, Ascletis will expand its production of the oral tablet ritonavir to produce 100 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 manufacturing roundup: Ritonavir production to reach 100M doses annually; Schumer calls for a boost to domestic vaccine supply

Josh Sullivan

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Covid-19 man­u­fac­tur­ing roundup: Ri­ton­avir pro­duc­tion to reach 100M dos­es an­nu­al­ly; Schumer calls for a boost to do­mes­tic vac­cine sup­ply

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Covid-19 manufacturing roundup: Ritonavir production to reach 100M doses annually; Schumer calls for a boost to domestic vaccine supply